NASDAQ:VRCA Verrica Pharmaceuticals Q3 2024 Earnings Report $5.18 -0.22 (-4.07%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$5.19 +0.01 (+0.27%) As of 07/29/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Verrica Pharmaceuticals EPS ResultsActual EPS-$4.90Consensus EPS -$3.70Beat/MissMissed by -$1.20One Year Ago EPSN/AVerrica Pharmaceuticals Revenue ResultsActual Revenue($1.78) millionExpected Revenue$7.53 millionBeat/MissMissed by -$9.31 millionYoY Revenue GrowthN/AVerrica Pharmaceuticals Announcement DetailsQuarterQ3 2024Date11/4/2024TimeAfter Market ClosesConference Call DateMonday, November 4, 2024Conference Call Time9:30AM ETUpcoming EarningsVerrica Pharmaceuticals' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Verrica Pharmaceuticals Earnings HeadlinesVerrica Pharmaceuticals (NASDAQ:VRCA) Stock Rating Lowered by Wall Street ZenJuly 25, 2026 | americanbankingnews.comVerrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...July 21, 2026 | markets.businessinsider.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. | Porter & Company (Ad)Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in IsraelJuly 21, 2026 | globenewswire.comVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...June 23, 2026 | markets.businessinsider.comVerrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common WartsJune 22, 2026 | quiverquant.comQSee More Verrica Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Verrica Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verrica Pharmaceuticals and other key companies, straight to your email. Email Address About Verrica PharmaceuticalsVerrica Pharmaceuticals (NASDAQ:VRCA) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments. Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions. The company conducts its clinical trials primarily in the United States and has engaged with regulatory authorities in Europe to support potential future filings. Verrica collaborates with contract research organizations and academic partners to execute its development programs and gather data on safety and efficacy. Founded in 2020 as a strategic spin-out from Aclaris Therapeutics, Verrica is headquartered in West Chester, Pennsylvania. The company’s management team brings deep expertise in dermatology drug development, clinical operations and commercial strategy. As Verrica moves toward potential product approvals, it aims to address significant unmet needs in pediatric and adult dermatology markets.View Verrica Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why SK hynix Could Be the Best AI Chip Stock to Buy NowWhy Bloom Energy May Be the Most Important AI Infrastructure StockAlphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?Seagate Technology Stock Surges as Earnings Beat Silences AI DoubtersCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to Come Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
